Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 20/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26135997 | 1.00 | NTRK1 (0.43) | NTRK1 | |
| SCHEMBL21752811 | 0.97 | NTRK1 (0.42) | NTRK1 | |
| SCHEMBL30032213 | 0.97 | NTRK1 (0.42) | NTRK1 | |
| SCHEMBL21765937 | 0.97 | NTRK1 (0.42) | NTRK1 | |
| SCHEMBL30033904 | 0.97 | NTRK1 (0.42) | NTRK1 | |
| SCHEMBL23673834 | 0.97 | NTRK1 (0.42) | NTRK1 | |
| SCHEMBL21752878 | 0.94 | NTRK1 (0.41) | NTRK1 | |
| SCHEMBL30032909 | 0.94 | NTRK1 (0.41) | NTRK1 | |
| SCHEMBL25457167 | 0.94 | NTRK1 (0.41) | NTRK1 | |
| SCHEMBL21752807 | 0.94 | NTRK1 (0.41) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3840832-B1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | BENEVOLENTAI BIO LTD (GB) | 2023-10-11 | — | — | EP | claimed |
| US-20230149398-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | BENEVOLENTAI BIO LIMITED (GB) | 2023-05-18 | — | — | US | claimed |
| EP-4093404-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | BenevolentAI Bio Limited (GB) | 2022-11-30 | — | — | EP | claimed |
| US-20210253572-A1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | BenevolentAl Bio Limited (GB) | 2021-08-19 | — | — | US | claimed |
| WO-2021148805-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | BENEVOLENTAI BIO LIMITED (GB) | 2021-07-29 | — | — | WO | claimed |
| EP-3840832-B1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | BENEVOLENTAI BIO LTD (GB) | 2023-10-11 | — | — | EP | disclosed |
| EP-3840832-B1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | BENEVOLENTAI BIO LTD (GB) | 2023-10-11 | — | — | EP | disclosed |
| US-20230149398-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | BENEVOLENTAI BIO LIMITED (GB) | 2023-05-18 | — | — | US | disclosed |
| US-20230149398-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | BENEVOLENTAI BIO LIMITED (GB) | 2023-05-18 | — | — | US | disclosed |
| US-20230149398-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | BENEVOLENTAI BIO LIMITED (GB) | 2023-05-18 | — | — | US | disclosed |
| EP-4093404-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | BenevolentAI Bio Limited (GB) | 2022-11-30 | — | — | EP | disclosed |
| US-20210253572-A1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | BenevolentAl Bio Limited (GB) | 2021-08-19 | — | — | US | disclosed |
| US-20210253572-A1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | BenevolentAl Bio Limited (GB) | 2021-08-19 | — | — | US | disclosed |
| WO-2021148805-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | BENEVOLENTAI BIO LIMITED (GB) | 2021-07-29 | — | — | WO | disclosed |
| WO-2020039209-A1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | BENEVOLENTAI BIO LIMITED (GB) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149398-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | TNK2, TNIK, TNK1 | NTRK1 15/4885 |
| US-20210253572-A1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | MUSK, TPM3, CSNK1A1 | NTRK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.